Insider Trading Alert - ENTA, CTSH And AGIO Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 4, 2014, 99 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $25.55 to $17,507,243.40.

Highlighted Stocks Traded by Insiders:

Enanta Pharmaceuticals (ENTA) - FREE Research Report

Luly Jay R., who is President and CEO at Enanta Pharmaceuticals, sold 15,000 shares at $42.52 on Nov. 4, 2014. Following this transaction, the President and CEO owned 529,338 shares meaning that the stake was reduced by 2.76% with the 15,000-share transaction.

The shares most recently traded at $42.86, up $0.34, or 0.79% since the insider transaction. Historical insider transactions for Enanta Pharmaceuticals go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 4,000
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 29,000
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 59,000

The average volume for Enanta Pharmaceuticals has been 294,700 shares per day over the past 30 days. Enanta Pharmaceuticals has a market cap of $788.5 million and is part of the health care sector and drugs industry. Shares are up 55.54% year-to-date as of the close of trading on Tuesday.

Enanta Pharmaceuticals, Inc., a biotechnology company, is engaged in the development of small molecule drugs for the infectious disease field. The company has a P/E ratio of 25.1. Currently, there are 2 analysts who rate Enanta Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ENTA - FREE

TheStreet Quant Ratings rates Enanta Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full Enanta Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cognizant Technology Solutions (CTSH) - FREE Research Report

Coburn Gordon, who is President at Cognizant Technology Solutions, sold 31,714 shares at $48.78 on Nov. 4, 2014. Following this transaction, the President owned 56,448 shares meaning that the stake was reduced by 35.97% with the 31,714-share transaction.

The shares most recently traded at $50.95, up $2.17, or 4.26% since the insider transaction. Historical insider transactions for Cognizant Technology Solutions go as follows:

  • 4-Week # shares sold: 45,000
  • 12-Week # shares sold: 45,000
  • 24-Week # shares bought: 7,500
  • 24-Week # shares sold: 91,607

The average volume for Cognizant Technology Solutions has been 5.1 million shares per day over the past 30 days. Cognizant Technology Solutions has a market cap of $29.7 billion and is part of the technology sector and computer software & services industry. Shares are down 3.96% year-to-date as of the close of trading on Tuesday.

Cognizant Technology Solutions Corporation provides information technology (IT), consulting, and business process services worldwide. The company operates in four segments: Financial Services, Healthcare, Manufacturing/Retail/Logistics, and Other. The company has a P/E ratio of 21.8. Currently, there are 11 analysts who rate Cognizant Technology Solutions a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CTSH - FREE

TheStreet Quant Ratings rates Cognizant Technology Solutions as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Cognizant Technology Solutions Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Agios Pharmaceuticals (AGIO) - FREE Research Report

Higgons John Duncan, who is Chief Operating Officer at Agios Pharmaceuticals, sold 13,000 shares at $81.71 on Nov. 4, 2014. Following this transaction, the Chief Operating Officer owned 143,835 shares meaning that the stake was reduced by 8.29% with the 13,000-share transaction.

The shares most recently traded at $83.46, up $1.75, or 2.1% since the insider transaction. Historical insider transactions for Agios Pharmaceuticals go as follows:

  • 4-Week # shares bought: 2,300
  • 4-Week # shares sold: 13,000
  • 12-Week # shares bought: 2,300
  • 12-Week # shares sold: 19,255
  • 24-Week # shares bought: 2,300
  • 24-Week # shares sold: 43,255

The average volume for Agios Pharmaceuticals has been 627,500 shares per day over the past 30 days. Agios Pharmaceuticals has a market cap of $2.9 billion and is part of the health care sector and drugs industry. Shares are up 244.22% year-to-date as of the close of trading on Tuesday.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. The company has a P/E ratio of 55.4. Currently, there is 1 analyst who rates Agios Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AGIO - FREE

TheStreet Quant Ratings rates Agios Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income. Get the full Agios Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Jim Cramer: Aramark Is a Great Company but It's Levered to Baseball

Jim Cramer: Aramark Is a Great Company but It's Levered to Baseball

Preferred Stock & Common Stock: What's the Difference?

Preferred Stock & Common Stock: What's the Difference?

It's Not Over Yet: Keep an Eye on FANG Stocks

It's Not Over Yet: Keep an Eye on FANG Stocks

5 Stocks That Are Screaming Buys Right Now

5 Stocks That Are Screaming Buys Right Now

Jim Cramer on the Markets: 2:45pm Is a Make or Break Level

Jim Cramer on the Markets: 2:45pm Is a Make or Break Level